( MENAFN - PR Newswire) ROSEMONT, Ill., May 28, 2024 /PRNewswire/ -- The American Association of Nurse Anesthesiology (AANA) recently updated its practice considerations addressing ketamine therapy to cite the most current studies, as AANA continues to support a patient-centered, interdisciplinary approach to providing care and treatment to persons with psychiatric disorders or chronic pain. Included in these revised considerations is the use of esketamine nasal spray, an FDA-approved treatment for treatment-resistant depression (TRD) in adults and depressive symptoms in patients with major depressive disorder (MDD).
Ketamine therapy has been shown to have antidepressive properties and is increasingly being used to treat psychiatric disorders, including major depressive disorder, bipolar disorder, treatment-resistant depression, and post-traumatic stress disorder. Certified Registered Nurse Anesthetists (CRNAs), also known as nurse anesthesiologists or nurse anesthetists, have extensive training in the delivery of pain management medications such as ketamine and management of associated side effects or complications. The updated practice considerations feature a greatly expanded pharmacologic review section.
"CRNAs are highly trained in delivering professional, compassionate anesthesia and related care and have the expertise to safely administer all forms of ketamine, making their involvement a valuable solution. Their ability to provide anesthesia services autonomously in va.
